Literature DB >> 2097720

Killing and regrowth of bacteria in vitro: a review.

W A Craig1, S C Ebert.   

Abstract

Minimum inhibitory and bactericidal concentrations do not describe the time course of a drug's antimicrobial activity against bacteria. Some antimicrobials exhibit concentration dependent killing over a wide range of concentrations (e.g. aminoglycosides and quinolones), while others show maximal killing at concentrations near the MIC (e.g. beta-lactams and glycopeptides). The aminoglycosides and quinolones can require high drug concentrations (about 10-fold higher than the MIC) to prevent the selection of resistant subpopulations of bacteria. Persistent suppression of bacterial growth after antimicrobial exposure is called the 'postantibiotic effect' (PAE) and varies in duration depending on the drug-organism combination, as well as the concentration and duration of drug exposure. Antimicrobials which are inhibitors of protein and nucleic acid synthesis exhibit prolonged PAEs with a large variety of bacteria. While beta-lactam antibiotics demonstrate PAEs with Gram-positive cocci, very short or no PAEs are observed with these drugs with Gram-negative bacilli. The only exception is that penem antibiotics can induce PAEs with some strains of Gram-negative bacilli, primarily Pseudomonas aeruginosa. Thus, the pharmacodynamic activity of an antimicrobial can vary markedly depending on the microorganism and the class of drug and its concentration.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2097720

Source DB:  PubMed          Journal:  Scand J Infect Dis Suppl        ISSN: 0300-8878


  90 in total

1.  Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens.

Authors:  Roland R Regoes; Camilla Wiuff; Renata M Zappala; Kim N Garner; Fernando Baquero; Bruce R Levin
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 2.  Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections.

Authors:  E Nuermberger; J Grosset
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-13       Impact factor: 3.267

Review 3.  Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.

Authors:  P S McKinnon; S L Davis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-10       Impact factor: 3.267

Review 4.  Continuous infusion of beta-lactam antibiotics.

Authors:  W A Craig; S C Ebert
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

5.  Pharmacodynamics and alternative antimicrobial dosing regimens.

Authors:  J Conly; S Shafran
Journal:  Can J Infect Dis       Date:  1995-01

Review 6.  [Pharmacokinetics and pharmacodynamics of antibiotic therapy].

Authors:  S Beck; S G Wicha; C Kloft; M G Kees
Journal:  Anaesthesist       Date:  2014-10       Impact factor: 1.041

7.  Evaluation of 12 beta-lactam antibiotics for Agrobacterium-mediated transformation through in planta antibacterial activities and phytotoxicities.

Authors:  Yoichi Ogawa; Masahiro Mii
Journal:  Plant Cell Rep       Date:  2004-10-05       Impact factor: 4.570

8.  In vivo pharmacodynamic profiling of doripenem against Pseudomonas aeruginosa by simulating human exposures.

Authors:  Aryun Kim; Mary Anne Banevicius; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

Review 9.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

10.  Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia.

Authors:  S Daenen; Z Erjavec; D R Uges; H G De Vries-Hospers; P De Jonge; M R Halie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.